These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 34212215)

  • 1. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.
    Moon SY; Kim KD; Yoo J; Lee JH; Hwangbo C
    Molecules; 2021 May; 26(9):. PubMed ID: 34068714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
    Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
    Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting JAK-STAT signal transduction in IBD.
    Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
    Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule drug discovery targeting the JAK-STAT pathway.
    Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
    Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
    Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
    Flamant M; Rigaill J; Paul S; Roblin X
    Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1.
    Hartwig O; Loretz B; Nougarede A; Jary D; Sulpice E; Gidrol X; Navarro F; Lehr CM
    J Control Release; 2022 May; 345():646-660. PubMed ID: 35339579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
    Talotta R
    Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
    Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
    Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
    J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SOCS Proteins to Control JAK-STAT Signalling in Disease.
    Durham GA; Williams JJL; Nasim MT; Palmer TM
    Trends Pharmacol Sci; 2019 May; 40(5):298-308. PubMed ID: 30948191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
    Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
    World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.